Kyverna is building a company singularly focused on freeing patients from the siege of autoimmune disease. With our platform of targeted cellular therapies, we are working diligently to address the complexities of the immune system as we strive to transform the standard of care with better treatment options designed to tame autoimmunity.
Based in the San Francisco East Bay, Kyverna was founded in 2018 on the premise that advances in cell engineering for cancer could be applied to autoimmune disease, where a vast number of conditions are not adequately treated by currently available therapies.
In January 2020, the company announced a Series A investment from Vida Ventures, Westlake Village BioPartners, and Gilead, followed by a Series B financing in January 2022 led by Northpond Ventures.
Cell therapy represents a sophisticated approach to treating autoimmune disease without requiring extreme procedures such as bone marrow or stem cell transplants. This new type of therapy involves engineering immune cells from a patient or healthy donor and infusing those cells to correct an identified defective or pathogenic mechanism. This therapeutic approach may help restore balance to the patient’s immune system and offer sustained therapeutic benefits, eliminating the need for chronic or suboptimal therapies.